For metastatic patients, the predictive value of PD-L1 expression is also partly related to the presence of an anti-tumor immune response, and suggests that it is essential to use therapeutic partners capable of converting a cold and/or immunosuppressed tumor microenvironment into a hot, activated immune context, in order to sensitize the tumor to PD-1 blockade. Here, CD274 is linked to neoplasm.